24.94

2.58% -0.66

After Hours: 24.82 -0.12 -0.48%

Catalyst Pharmaceuticals Inc (CPRX)

Overview News Price History Option Chain Financials Why CPRX Down? Discussions Forecast

Catalyst Pharmaceuticals Inc stock is traded at $24.94, with a volume of 1.28M. It is down -2.58% in the last 24 hours and up +0.69% over the past month. Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Previous Close:

$25.60

Open:

$25.54

24h Volume:

1.28M

Relative Volume:

1.05

Market Cap:

$3.05B

Revenue:

$588.99M

Net Income/Loss:

$214.33M

P/E Ratio:

14.81

EPS:

1.6844

Net Cash Flow:

$208.61M

1W Performance:

+1.01%

1M Performance:

+0.69%

6M Performance:

+22.50%

1Y Performance:

+16.27%

1-Day Range:

$24.83

$25.57

1-Week Range:

$24.54

$25.82

52-Week Range:

$19.05

$26.58

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Name

Catalyst Pharmaceuticals Inc

Sector

Healthcare (1106)

Industry

Biotechnology (623)

Phone

(305) 529-2522

Address

355 ALHAMBRA CIRCLE, CORAL GABLES

Employee

182

Twitter

@CatalystForRare

Next Earnings Date

2024-11-06

Latest SEC Filings

CPRX's Discussions on Twitter

Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CPRX Catalyst Pharmaceuticals Inc	24.94	3.05B	588.99M	214.33M	208.61M	1.6844
VRTX Vertex Pharmaceuticals Inc	436.27	110.97B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	748.87	79.17B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	799.65	49.73B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	322.11	42.98B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	309.66	34.37B	5.36B	287.73M	924.18M	2.5229

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-04-25	Initiated	Robert W. Baird	Outperform
Nov-18-24	Initiated	Stephens	Overweight
Mar-14-24	Initiated	Citigroup	Buy
Mar-07-24	Initiated	BofA Securities	Buy
Dec-21-23	Initiated	Oppenheimer	Outperform
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral
Sep-30-14	Reiterated	ROTH Capital	Buy
Sep-16-14	Reiterated	ROTH Capital	Buy
Sep-15-14	Reiterated	H.C. Wainwright	Buy
Oct-21-13	Reiterated	Aegis Capital	Buy
Sep-24-13	Initiated	Maxim Group	Buy
Sep-06-13	Reiterated	Aegis Capital	Buy
Apr-18-13	Initiated	Aegis Capital	Buy
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Hapoalim	Neutral → Underperform
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell
Dec-15-08	Initiated	Merriman Curhan Ford	Buy
Nov-28-07	Initiated	Rodman & Renshaw	Mkt Outperform
Jan-31-07	Initiated	Stifel Nicolaus	Buy
Jan-05-07	Initiated	First Albany	Buy

View All

Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News

Apr 12, 2026

Jim Cramer on Catalyst Pharmaceuticals: "It's a very inexpensive stock" - MSN

Apr 12, 2026

Apr 10, 2026

If You Invested $1000 in Catalyst Pharmaceutical 10 Years Ago, This Is How Much You'd Have Now - qz.com

Apr 10, 2026

Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Apr 10, 2026

KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200 - TradingView — Track All Markets

Apr 10, 2026

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top Affordable Growth Stock - ChartMill

Apr 10, 2026

Apr 09, 2026

Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 09, 2026

Price Action: Will Catalyst Pharmaceuticals Inc benefit from government policy2026 Trading Volume Trends & Reliable Price Breakout Signals - baoquankhu1.vn

Apr 09, 2026

ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know - TradingView — Track All Markets

Apr 09, 2026

(CPRX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Apr 09, 2026

Apr 08, 2026

Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch

Apr 08, 2026

Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum - Sahm

Apr 08, 2026

Apr 07, 2026

Bear Alert: Is Catalyst Pharmaceuticals Inc currently under institutional pressure2026 Major Catalysts & Daily Risk Controlled Trade Plans - baoquankhu1.vn

Apr 07, 2026

Catalyst Pharmaceuticals (CPRX) Is Up 5.0% After Extending Firdapse Exclusivity And Launching AgamreeHas The Bull Case Changed? - Yahoo Finance

Apr 07, 2026

Apr 06, 2026

Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget

Apr 06, 2026

IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - TradingView — Track All Markets

Apr 06, 2026